<DOC>
	<DOC>NCT02974868</DOC>
	<brief_summary>Study B7931005 will investigate the JAK3 inhibitor PF- 06651600 and TYK2/JAK1 inhibitor PF-06700841 in Alopecia Areata. This Phase 2a, randomized, double blind, parallel group, multicenter study will enroll a total of approximately 132 subjects (expect to provide approximately 90 completers). The study will be conducted at approximately 30 to 40 sites.</brief_summary>
	<brief_title>Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata</brief_title>
	<detailed_description />
	<mesh_term>Alopecia</mesh_term>
	<mesh_term>Alopecia Areata</mesh_term>
	<criteria>Male or female subjects between 18 75 years of age, inclusive, at time of informed consent. Must have moderate to severe alopecia areata: History of human immunodeficiency virus (HIV) or positive HIV serology at screening, Infected with hepatitis B or hepatitis C viruses. Have evidence of active or latent or inadequately treated infection with Mycobacterium tuberculosis (TB) Have received any of the following treatment regiments specified in the timeframes outlined below: Within 6 months of first dose of study drug: Any cell depleting agents Within 12 weeks of first dose of study drug: Any studies with JAK inhibitors; Other biologics Within 8 weeks of first dose of study drug: Participation in other studies involving investigational drug(s) Within 6 weeks of first dose of study drug: Have been vaccinated with live or attenuated live vaccine. Within 4 weeks of first dose of study drug: Use of oral immune suppressants; Phototherapy (NB UVB) or broad band phototherapy; Regular use (more than 2 visits per week) of a tanning booth/parlor. Within 2 week of first dose of study drug: Topical treatments that could affect AA; Herbal medications with unknown properties or known beneficial effects for AA.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Phase 2</keyword>
	<keyword>randomized</keyword>
	<keyword>double-blind</keyword>
	<keyword>placebo</keyword>
	<keyword>alopecia areata</keyword>
	<keyword>safety</keyword>
	<keyword>efficacy</keyword>
	<keyword>JAK</keyword>
	<keyword>janus kinase</keyword>
	<keyword>moderate</keyword>
	<keyword>severe</keyword>
</DOC>